What You Should Know:
– President Donald J. Trump announced the latest in a series of significant actions to lower prescription drug prices, unveiling agreements with pharmaceutical manufacturers Eli Lilly and Company and Novo Nordisk.
–…
Continue Reading
If you’ve been following us on our social media channels (John Lynn, Colin Hung, and Healthcare IT Today), you’ll know that last week we were connecting and learning with the health IT professionals at…
Continue Reading
Introduction
In a groundbreaking move that reshapes direct-to-consumer pharmaceutical access, Eli Lilly has partnered with Walmart to offer in-store pickup services for Zepbound vials. This collaboration represents the first retail pharmacy partnership for LillyDirect, Eli…
What You Should Know:
– Tandem Diabetes Care, an insulin delivery and diabetes technology company, has announced that its t:slim X2™ insulin pump with Control-IQ+ automated insulin delivery (AID) technology is now cleared for use…
Continue Reading
What You Should Know:
– Eli Lilly and Company has announced positive topline results from its Phase 3 ATTAIN-2 trial, which evaluated orforglipron, an investigational oral GLP-1 receptor agonist, in adults with obesity or overweight…
Continue Reading
Persist AI, an AI-driven robotics platform for the pharmaceutical industry, announced an overscribed $12 million Series A funding round.Spero Ventures led the round with participation from MBX Capital, Shimadzu Future Innovation Fund managed by…
Continue Reading
Persist AI, an AI-driven robotics platform for the pharmaceutical industry, announced an overscribed $12 million Series A funding round.Spero Ventures led the round, with participation from MBX Capital, Shimadzu Future Innovation Fund managed by…
Continue Reading
Patent Monopolies Drive Record Profits
Novo Nordisk and Eli Lilly have transformed GLP-1 receptor agonists into unprecedented profit machines. These blockbuster drugs, approved for diabetes and weight loss, generate billions while leaving many patients unable…
Indianapolis-based pharmaceutical behemoth Eli Lilly has filed lawsuits against four compounders claiming that they sold unapproved products that contain tirzepatide, a key ingredient in the company’s weight-loss and diabetes drugs, including top-seller Mounjaro.The lawsuits against…
Continue Reading
Top News
Eli Lilly sues four telehealth startups — Mochi Health, Willow Health, Fella & Delilah Health, and Henry Meds — for selling compounded versions of its $1,000-per-month GLP-1 weight loss drug Zepbound.
The FDA…
